The effect of magnesium in controlling asthma

A clinical trial of the study of the effect of magnesium supplementation on asthma

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170827035935N2

Enrollment

Registered

2018-02-10

Start date

2017-03-20

Completion date

Unknown

Last updated

2018-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma. Asthma, unspecified, Acute severe asthma

Interventions

Intervention 1: Intervention group: Magnesium Supplement with Brand Magne B6, product of Sanofi Aventis Pharmaceutical Factory, containing 470 mg of lactate magnesium, equivalent to 48 mg of magnesium

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients with asthma

Exclusion criteria

Exclusion criteria: Use of oral corticosteroids Use Diuretics Renal failure Congestive heart failure Use of magnesium supplement in the past quarter History of using cigarettes Pregnancy The decision to have a pregnancy

Design outcomes

Primary

Measure	Time frame
Severity of asthma. Timepoint: At the beginning of the study (before the intervention) and at weeks 4, 8 and 12 after the intervention. Method of measurement: PEFR measurements by peak flow meter.;FEV1/FVC. Timepoint: Before and immediately after the intervention. Method of measurement: Spirometry.;The number of asthma attacks. Timepoint: At the beginning of the study (before the intervention) and at weeks 4, 8 and 12 after the intervention. Method of measurement: Ask the patient.;ACT-Score. Timepoint: At the beginning of the study (before the intervention) and at weeks 4, 8 and 12 after the intervention. Method of measurement: ACT questionnaire.;FEV1. Timepoint: Before and immediately after the intervention. Method of measurement: Spirometry.;FVC. Timepoint: Before and immediately after the intervention. Method of measurement: Spirometry.	—

Measure

Time frame

Severity of asthma. Timepoint: At the beginning of the study (before the intervention) and at weeks 4, 8 and 12 after the intervention. Method of measurement: PEFR measurements by peak flow meter.;FEV1/FVC. Timepoint: Before and immediately after the intervention. Method of measurement: Spirometry.;The number of asthma attacks. Timepoint: At the beginning of the study (before the intervention) and at weeks 4, 8 and 12 after the intervention. Method of measurement: Ask the patient.;ACT-Score. Timepoint: At the beginning of the study (before the intervention) and at weeks 4, 8 and 12 after the intervention. Method of measurement: ACT questionnaire.;FEV1. Timepoint: Before and immediately after the intervention. Method of measurement: Spirometry.;FVC. Timepoint: Before and immediately after the intervention. Method of measurement: Spirometry.

—

Secondary

Measure	Time frame
-. Timepoint: -. Method of measurement: -.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Ali Sharif Pour

Mazandaran University Of Medical Science

hamed.jafarpour7@gmail.com+98 11 3448 4864

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026